TORAY INDUSTRIES, INC.

Cogent Bio Presents Bezuclastinib Data Highlighting Long-Term Benefits in Non-Advanced Systemic Mastocytosis

4 months ago

• Cogent Biosciences will present a poster on bezuclastinib at the AAAAI Annual Meeting, focusing on long-term symptomatic benefits in NonAdvSM patients. • The poster highlights efficacy and safety results from the ongoing SUMMIT trial in adult NonAdvSM patients receiving 100mg of bezuclastinib. • Cogent anticipates top-line results from the SUMMIT trial in July 2025 and plans to submit an NDA for bezuclastinib by the end of 2025. • Expanded Access Programs for bezuclastinib are expected to launch in the U.S. in Q1 2025 for Systemic Mastocytosis and Gastrointestinal Stromal Tumors patients.